Nutriband (NTRB) AI Stock Analysis

• Market Cap: $86.89M
• Dividend Yield: N/A
• Average Volume (3M): 58.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 18.92%
• EPS Growth: -17.30%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 11,154,171
• 10 Day Avg. Volume: 34,001
• 30 Day Avg. Volume: 58,973
• PEG Ratio: 0.14
• Price to Book (P/B): 3.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.07
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 3.48
• Enterprise Value/Gross Profit: 36.87
• Enterprise Value/Ebitda: -0.87
• 1Y Price Target: $15.00
• Price Target Upside: 92.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: $8.50 ▲(9.11%Upside)

Nutriband's stock score is primarily impacted by its financial challenges, including profitability and cash flow issues, despite a stable balance sheet. The technical indicators are positive, suggesting strong momentum, yet the valuation reflects significant concerns with ongoing losses. Corporate events add a favorable note but are not significantly influential overall.

Positive Factors

Market Potential

Analyst believes AVERSA Fentanyl can be the first abuse-deterrent transdermal fentanyl patch, which could lead to taking market share from the current generic transdermal patches.

Partnership

Nutriband has a partnership with Kindeva Drug Delivery, formerly part of 3M, to add the AVERSA technology to Kindeva’s transdermal fentanyl patch.

Product Development

The AVERSA Fentanyl patch could prevent abuse and accidental misuse of fentanyl transdermal patches, potentially allowing for decreased restrictions and improved access for patients with severe chronic pain.

Negative Factors

Regulatory Pathway

Analysts believe the Phase 1 clinical trial will show sufficient abuse deterrence for Nutriband to file a New Drug Application using the 505(b)(2) pathway for approval.

Nutriband Business Overview & Revenue Model

Company Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

How the Company Makes Money

Nutriband makes money through the development, manufacture, and sale of its transdermal delivery products. The company generates revenue by selling its pharmaceutical delivery systems to healthcare providers, pharmaceutical companies, and distributors. Key revenue streams include the sale of its proprietary transdermal patches, licensing agreements for its drug delivery technology, and partnerships with other pharmaceutical companies to develop and commercialize new transdermal products. Additionally, Nutriband may receive milestone payments and royalties from partnerships and licensing deals, contributing to its earnings.

Nutriband Financial Statement Overview

Summary

Nutriband exhibits slow revenue growth with significant challenges in profitability and cash flow. The balance sheet is stable with low leverage, but persistent losses and reliance on external financing are critical concerns.

Income Statement

Nutriband has shown modest revenue growth over the years, but profitability remains a challenge with consistently negative EBIT and net income margins. Revenue increased by 2.6% from 2024 to 2025, indicating slow growth. However, the gross profit margin has been volatile, and the net profit margin remains deeply negative, reflecting the company's difficulty in managing costs in relation to revenues.

Balance Sheet

The balance sheet is relatively stable, with a low debt-to-equity ratio indicating conservative leverage. Stockholders' equity remains strong at approximately 86% of total assets. However, the company's return on equity is negative due to ongoing net losses, which could be concerning for long-term sustainability.

Cash Flow

Nutriband's cash flow situation is challenging, with negative operating and free cash flows reflecting ongoing operational losses. The operating cash flow to net income ratio is negative, indicating cash outflows exceed net losses. The company relies heavily on financing cash flows to offset operating cash deficits, which is not sustainable long-term.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
2.40M	2.14M	2.09M	2.08M	1.42M	943.70K
	Gross Profit
788.61K	699.30K	862.11K	750.41K	504.31K	361.32K
	EBIT
-6.21M	-6.69M	-4.87M	-4.15M	-3.93M	-2.60M
	EBITDA
-9.68M	-10.18M	-5.12M	-4.11M	-5.74M	-2.48M
	Net Income Common Stockholders
-9.97M	-10.48M	-5.49M	-4.81M	-8.42M	-3.21M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.96M	4.31M	492.94K	1.99M	4.89M	151.99K
	Total Assets
6.15M	7.47M	7.52M	9.46M	12.74M	9.93M
	Total Debt
282.44K	186.35K	241.28K	185.81K	134.57K	1.79M
	Net Debt
-2.68M	-4.13M	-251.66K	-1.80M	-4.76M	1.64M
	Total Liabilities
1.05M	1.04M	1.08M	883.39K	880.38K	2.82M
	Stockholders Equity
5.10M	6.43M	6.44M	8.57M	11.86M	7.11M
Cash Flow		Free Cash Flow
-5.22M	-4.72M	-3.58M	-3.07M	-2.89M	-297.06K
	Operating Cash Flow
-5.13M	-4.63M	-3.53M	-2.99M	-2.81M	-297.06K
	Investing Cash Flow
-91.17K	-92.04K	-51.76K	-79.30K	-81.59K	66.99K
	Financing Cash Flow
-162.86K	8.54M	2.09M	160.07K	7.63M	371.87K

Nutriband Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Positive. The current price of 7.79 is above the 20-day moving average (MA) of 7.21, above the 50-day MA of 6.21, and above the 200-day MA of 5.90, indicating a bullish trend. The MACD of 0.45 indicates Positive momentum. The RSI at 61.10 is Neutral, neither overbought nor oversold. The STOCH value of 65.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTRB.

Nutriband Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRB	55 Neutral	$86.89M	―	-108.02%	―	18.92%	-17.30%
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%
DOMH		$91.52M	―	-92.68%	―	―	―
SER	54 Neutral	$57.31M	―	45.59%	―	34.04%	55.34%
AVTX	47 Neutral	$51.54M	―	678.24%	―	-69.59%	―
ANRO	42 Neutral	$61.45M	―	-38.04%	―	―	―
CBUS	40 Underperform	$73.65M	―	-157.73%	―	104.78%	40.41%

Nutriband Corporate Events

Nutriband Partners with Charlotte FC for Brand Visibility

On April 4, 2025, Nutriband Inc. announced an Associate Partnership agreement with Charlotte FC to enhance brand visibility for its products, including AI Tape, which is manufactured in the Charlotte area. This partnership aims to promote Nutriband’s platform technology AVERSA, potentially the world’s first abuse deterrent patch platform for chronic pain management, thereby strengthening its market presence and stakeholder engagement.